TAAR1 agonists for stopping cocaine use
Official title: TAAR1 Agonists for the Treatment of Stimulant Use Disorder
Funded at Psychogenics, INC. · NIH-11283316 · Data updated 2026-11-12
A promising drug approach is being tested to help people with cocaine use disorder reduce or stop their cocaine use.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Psychogenics, INC. NIH-funded |
| Lab location | 1 site (Paramus, UNITED STATES) |
| Project start | June 15, 2026 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $398,947 |
| NIH project number | 1R43DA061847-01A1 |
| Project ID | NIH-11283316 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals with cocaine use disorder who could benefit from a pharmacologic treatment in the future.
✕Less likely to help
People without cocaine use disorder or those not seeking pharmacological treatment options may not benefit.
What this research studies
This NIH grant funds preclinical work on two novel drug molecules that may help people who struggle with cocaine use disorder. Researchers will test how these compounds affect cocaine-taking and relapse-like behaviors in animal models, focusing on self-administration and stress-triggered relapse. If a dose shows strong effects, they will explore its potential to prevent relapse after a drug-free period. The goal is to identify a safe, effective pharmacological option to support abstinence in people with cocaine use disorder.
Why it matters
Potential benefit: If successful, the work could lead to a new medication that helps reduce cocaine use and supports lasting abstinence.
How similar studies have gone: Previous research in this area has shown that targeting novel mechanisms can reduce drug-taking and relapse in models, supporting the potential for success.
Where this research is happening
-
Psychogenics, INC.
Paramus, United States Active
Researchers
- Principal investigator: Gresack, Jodi Ellen — Psychogenics, INC.
- Study coordinator: Gresack, Jodi Ellen
Related research
Other NIH-funded projects on the same topics.
-
EEG-based drug repurposing for rare CNS diseases
A new approach uses EEG brain signatures to find existing drugs that might help people with rare nervous-system disorders.
-
Investigating new treatments for pain management.
This study is looking for new ways to help manage pain better, and it could lead to improved treatments for people dealing with chronic pain.
-
Analyzing brain wave patterns to find new uses for existing drugs in rare diseases
This study is looking to find new ways to use existing medications for rare diseases and mental health conditions by analyzing brain wave patterns from animal models, making it easier and cheaper to discover helpful treatments for people like you.
-
Using machine learning to design new drugs for psychiatric disorders
This study is working on using smart computer techniques to help create better and safer medications for mental health conditions, so patients can have more effective treatment options that really fit their needs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.